New FDA-approved obesity drug: what the TikTok buzz gets right and wrong

What did @taniahenscheldefreitas actually say?

Honestly, this is a problem before the fact-check even starts. The transcript from this video is incoherent. Phrases like "engaging the girl who's married to the girls" and "my mom is a young girl" have no medical meaning. The caption claims this is about "a new medication approved by the FDA for obesity and overweight," but the spoken content does not support, explain, or even gesture toward that claim in any verifiable way.

What we can work with is the caption and hashtags: the creator positioned this as breaking news about an FDA approval in the GLP-1 or weight management space. That framing is what we're fact-checking here, because the audio provides nothing to verify or dispute on its own merits.

Does the science back this up?

The FDA has approved several medications for chronic weight management in recent years, so the general claim is not implausible. The question is which drug, what the actual approval means, and whether the framing is accurate. Without a named drug in the transcript, we're left auditing a category.

Here is what is established: semaglutide (Wegovy) received FDA approval for chronic weight management in adults in June 2021. Tirzepatide (Zepbound) received FDA approval for the same indication in November 2023 (Jastreboff et al., 2022, New England Journal of Medicine). Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, showed significant weight loss in Phase 2 trials (Jastreboff et al., 2023, NEJM) but has not yet received FDA approval as of early 2025. If the creator was referencing tirzepatide's approval or an anticipated approval of a newer agent, that could be contextually accurate. But we cannot confirm this from what was actually said in the video.

What did they get wrong (or right)?

The caption framing, that a "new medication" was approved by the FDA for obesity, is broadly consistent with the regulatory landscape of 2023 to 2024. The FDA did approve Zepbound (tirzepatide) in late 2023, which was genuinely significant. Credit where it is due: pointing people toward FDA-approved treatments rather than unregulated supplements is directionally responsible.

What is wrong, or at least deeply problematic, is the gap between the caption's promise and what the video actually delivers. Viewers searching for real information about a new obesity drug approval got nothing actionable. No drug name. No mechanism. No clinical context. A caption that says "FDA approved" with no supporting content is not informative, it is engagement bait dressed up as health news. That matters in a category where misinformation has real consequences for people making treatment decisions.

What should you actually know?

If you saw this video and wanted actual information, here it is. Tirzepatide (Zepbound) is currently the most recently FDA-approved GLP-1 class agent for weight management in adults without diabetes. In the SURMOUNT-1 trial, adults with obesity taking tirzepatide lost up to 22.5% of body weight over 72 weeks (Jastreboff et al., 2022, NEJM). That is a clinically meaningful number.

These are not lifestyle supplements. They are prescription medications with real side effect profiles, including nausea, vomiting, pancreatitis risk, and potential thyroid concerns. They are also not permanent fixes: data from the STEP 4 trial showed that stopping semaglutide leads to significant weight regain within a year (Rubino et al., 2021, JAMA).

• FDA-approved options include semaglutide (Wegovy) and tirzepatide (Zepbound) for weight management.
• Compounded versions of these drugs are not equivalent to brand-name formulations and are not FDA-approved.
• Any new approval should be verified directly at fda.gov, not via social media captions.